Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.
about
How to select the best available related or unrelated donor of hematopoietic stem cells?Cord Blood as a Source of Natural Killer CellsSelection and expansion of natural killer cells for NK cell-based immunotherapyEffector Functions of Natural Killer Cell Subsets in the Control of Hematological MalignanciesNK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyImproving the outcome of leukemia by natural killer cell-based immunotherapeutic strategiesKiller immunoglobulin-like receptors and tumor immunityImmunotherapeutic applications of NK cellsOutcomes from unrelated donor hematopoietic stem cell transplantationTargeted immunotherapy for acute myeloid leukemiaMilestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current DevelopmentsIdentification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime?Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular TherapyImproving natural killer cell cancer immunotherapyDifferent patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locusLeukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.Role of major histocompatibility complex variation in graft-versus-host disease after hematopoietic cell transplantation.Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation.Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimenDonor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemiaNatural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantationDonor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantationReduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.Biology and clinical effects of natural killer cells in allogeneic transplantation.Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrNatural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo.Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioMaternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2.How closely related is graft-vs-leukemia to donor/recipient disparity?Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection.High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant?HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.Natural killer cell-based therapies.Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation.KIR, HLA, and IL28B variant predict response to antiviral therapy in genotype 1 chronic hepatitis C patients in Japan.Humans differ from other hominids in lacking an activating NK cell receptor that recognizes the C1 epitope of MHC class I
P2860
Q26744109-B070FE40-7F58-4205-8C61-F0B20E9AA063Q26771337-9951DE7F-3532-48DC-9A8A-E77AAE58FB3DQ26774777-C652A6C1-87A0-4783-B6AD-22A20A25292FQ26776538-FBE3D031-0DF9-4735-BBD7-D6D927930FECQ26797345-3649FE18-51DF-4B36-B437-6A1E9F7A6D69Q26996660-D265BBB2-7586-49A3-8DCA-42204183AEB8Q27005792-EA58F058-2A1F-42E6-871A-828CD1790719Q27015908-BD016F5B-20F1-430F-AB82-A25ED0A74A82Q27027854-57EE9C95-DD9F-4D03-ACB8-BB7B678F4D10Q27687636-F7638D96-6A7F-4C5E-A13F-6CA6A9CED641Q28067102-C51313E0-9763-4DC9-A80D-F6B723D76CCBQ28080914-3679576D-487A-4921-AE7B-FAB89C8A0FDAQ28085397-B6262AF4-D431-49F3-9238-85138661599DQ28087719-BE03BF50-CB1C-4608-8E67-47869D7C895DQ28743897-2CA0F960-5BAB-44CC-B4B7-77D3C24B342CQ33558780-9EEAA73E-E274-418A-9367-FCD1489BBA86Q33642419-34B0AECD-F522-490C-89FE-DBE99AC89C31Q33643203-00DE8327-9A5A-4E1E-B54B-CD8E843B55E4Q33645271-30F298BD-D592-4F25-9B5A-B077A0A9BB41Q33651178-0C06645C-F109-42AA-96CF-EE39A2A6D4A3Q33672480-74AE0C36-8F2E-4C54-BEA4-D9143CD92AD9Q33703046-EF1CD567-37BB-47FD-9BBF-B4DD955FDE12Q33765556-1703AFF1-7892-4406-87F7-F87F3A206329Q33805980-7B3C7D82-B7A9-43A0-8EEF-6437B5EC3C2FQ33841389-17D8A28A-8B55-4F9C-BDAE-E2488627E6E7Q33893173-537807A2-F507-4ED5-B25B-3D86C87E2C36Q34009595-714274E2-6FB7-4D0A-9ABC-7650CDC02F50Q34044024-682C5773-09FA-4E5E-AE7A-102B2694249BQ34087767-1128CEEF-959A-4896-B823-F809660B4388Q34193507-473C2EA2-10A4-4B5A-BD5D-3F681D564E22Q34202277-DE16118A-586C-4C8E-9FF1-51790046C826Q34245469-3B48D096-588C-4A88-89E1-8D0B2EDADFF6Q34412313-B0845EE3-3E80-4C6C-BE73-56BE4C5DD9FAQ34577711-CA724150-4A37-4B9C-9163-3C5C4A6B44AAQ34645259-9F67A521-D55E-4306-AD4D-EEFF56B5D519Q34768153-A006C42D-11CF-426C-8795-C0C2053608DEQ34988727-BE773B6D-5453-40F9-8302-4D31473FA312Q35029441-0D4DA724-99B8-4FD5-9FE3-243F700051D7Q35070933-A207C90A-E4A7-4C78-AD6E-DE72119F1D10Q35071326-CB39B529-42E5-4974-97B0-9AE11755D0AC
P2860
Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Donors with group B KIR haplot ...... or acute myelogenous leukemia.
@ast
Donors with group B KIR haplot ...... or acute myelogenous leukemia.
@en
type
label
Donors with group B KIR haplot ...... or acute myelogenous leukemia.
@ast
Donors with group B KIR haplot ...... or acute myelogenous leukemia.
@en
prefLabel
Donors with group B KIR haplot ...... or acute myelogenous leukemia.
@ast
Donors with group B KIR haplot ...... or acute myelogenous leukemia.
@en
P2093
P2860
P50
P1433
P1476
Donors with group B KIR haplot ...... or acute myelogenous leukemia.
@en
P2093
Daniel J Weisdorf
Elizabeth Trachtenberg
John Klein
Koy Saeteurn
Lisbeth A Guethlein
Peter Parham
Sarah Cooley
P2860
P304
P356
10.1182/BLOOD-2008-07-171926
P407
P577
2008-10-22T00:00:00Z